Regeneron Pharmaceuticals, Inc. (REGN) 주식 — 좋은 사업일까?

Regeneron Pharmaceuticals, Inc. (REGN) 주식 — 좋은 사업일까? — InspectStocks

Just reported

Q3 2026 results

From Regeneron Pharmaceuticals's results release of 2026년 10월 30일; its quarterly report has since been filed.

Revenue
Actual
US$5.12B
+36% y/y
+19% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$18.45
+35% y/y
+51% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$2.05B
+99% y/y
+58% q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

어떻게 돈을 버는가

Collaboration revenue47%
Product revenue38%
Libtayo net product sales11%
Product and service other4%
Lynozyfic0%

매출 비중은 quarter ended March 31, 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가6

Dupixent
An injected medicine used for several allergic and inflammatory conditions, including eczema, asthma, and chronic obstructive pulmonary disease.
EYLEA HD
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
EYLEA
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.

3개 더 보기

Libtayo
An immune-system cancer medicine used for several cancers, including certain skin cancers and lung cancer.
Praluent
An injected medicine that lowers cholesterol and reduces cardiovascular risk in some patients.
Otarmeni
A gene therapy for hearing loss caused by changes in the otoferlin gene.

누가 사는가2

Drug wholesalers and specialty distributors buy medicines for supply to pharmacies, hospitals, and other healthcare providers.
Pharmacies, hospitals, government agencies, physicians, and other healthcare providers buy or use Regeneron medicines for patients.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1A small number of customers together accounted for 77% (year ended December 31, 2025, high) of gross product revenue.
2Sales depend substantially on Dupixent, EYLEA HD, and EYLEA, and on continued commercial work with Sanofi and Bayer.
3Some medicines rely on single-source suppliers and on collaborators or contractors for filling, packaging, testing, and distribution.
4Sales depend on health insurers and government programs deciding whether to cover medicines and how much to reimburse.

잘못될 수 있는 일

1EYLEA faces competition from other retinal medicines and biosimilars; the company has reported lower EYLEA sales as patients switch to EYLEA HD and other treatments compete for use.
2A large share of revenue depends on a few medicines and on partner arrangements, so lower sales, reduced reimbursement, or a change to a collaboration could materially affect revenue.
3Clinical studies can fail and regulators can delay or reject applications; recent examples include a fianlimab cancer study that missed its main goal and discontinued development of itepekimab in several respiratory conditions.

전체 재무제표 보기 →

Regeneron Pharmaceuticals, Inc. 소개

Regeneron discovers, develops, makes, and sells medicines for conditions including eye diseases, allergic and inflammatory diseases, and cancer. Its medicines include Dupixent for inflammatory diseases, EYLEA for retinal conditions, and Libtayo for cancer. It sells some medicines itself and shares sales profits with partners such as Sanofi and Bayer, which also sell certain medicines.

본사: Tarrytown, New York
설립: 1988
상장 시장: NASDAQ
회계연도 종료: December 31

Regeneron Pharmaceuticals, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Just reported

Q3 2026 results

From Regeneron Pharmaceuticals's results release of 2026년 10월 30일; its quarterly report has since been filed.

Revenue
Actual
US$5.12B
+36% y/y
+19% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$18.45
+35% y/y
+51% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$2.05B
+99% y/y
+58% q/q
Guided
—
No guide given

Keep exploring

The themes Regeneron Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises